Key points from article :
The Dog Aging Project (DAP), led by researchers from Texas A&M University, has received a $7 million grant from the National Institutes of Health to expand its clinical trial on rapamycin, a drug being studied for its potential to extend the lifespan of companion dogs. Since its launch in 2019, the DAP has enrolled over 50,000 dogs to study the effects of aging and understand factors contributing to a healthy and long canine life, with insights that may also inform human aging research. The current study, TRIAD, builds on previous findings that small doses of rapamycin improve cardiac function in dogs and may delay aging-related cognitive and physical decline.
Rapamycin, often used in human organ transplants as an immunosuppressant, is believed to mimic some benefits of intermittent fasting at a cellular level, enhancing heart muscle function and overall health. Researchers aim to expand the trial from 170 dogs at 20 sites to 580 dogs across the U.S., with participating dogs requiring regular health assessments over three years. The project is supported by institutions such as the University of Washington School of Medicine and the University of Wisconsin, making it a collaborative effort across veterinary and human medical fields.
The trial targets dogs over 7 years old, in good health, and weighing at least 44 pounds, as they share age-related changes similar to humans, including cognitive and mobility challenges. Results from the TRIAD trial are expected to provide valuable insights into both veterinary and human aging, potentially improving heart disease management and delaying cognitive decline.
The collaboration of dog owners is crucial to its success. Additional sites are being added to accommodate the expanded trial, with the possibility of further enrollment through the DAP website. This effort reflects a unique partnership between scientists and pet owners, driving discoveries that benefit both canine and human health.
